Pfizer Medical Information

Health Care Professionals Log In

Sign Up for RELISTOR Updates

Gain access to additional content on the RELISTOR Web site and receive updates. You’ll also get at no charge, unlimited access to:

  • The 5–Minute Clinical Consult
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets

Register Now

Give your patients the opportunity to save up to $20 on their RELISTOR prescription.

RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond 4 months has not been studied.

  • Print out 10 coupons to give to your patients.
  • The coupon is good for a $20 co-pay discount off a prescription of a minimum of 1 Retail Kit.
  • Each Retail Kit contains 7 vials of RELISTOR.

Log In to Download the Coupons
E-mail Address
Password:
  Forgot your password?
     
Not Registered? Click here to register for a free Wyeth account.
 

Terms and Conditions: Offer not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicare, Medicaid, any other federal or state program or by private plans or other health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs. You must deduct the value of this offer from any reimbursement requests submitted to your insurance plan either by you or on your behalf. Offer void in Massachusetts or where otherwise prohibited by law. This offer is not health insurance. Offer good only in USA. Co-pay offer limited to one per person during offering period and is not transferable. Offer limited to one use. Offer expires 9/30/2010. Wyeth Pharmaceuticals reserves the right to terminate this offer at any time without notice. You understand and agree to comply with these terms and conditions.

Indication

RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR
beyond 4 months has not been studied.

Important Safety Information for RELISTOR

  • RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
  • If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
  • Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients. Use RELISTOR with caution in patients with known or suspected lesions of the GI tract
  • Use of RELISTOR has not been studied in patients with peritoneal catheters
  • The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), diarrhea (5.5% vs 2.4%), and hyperhidrosis (6.7% vs 6.5%)
  • Safety and efficacy of RELISTOR have not been established in pediatric patients

Please see the full Prescribing Information.